Prothena Corporation plc

Prothena Corporation plc

PRTA

Market Cap$457.53M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Prothena Corporation plcProthena Corporation plc-3.7--27%3.6-
$35.32

Current Fair Value

397.5% upside

Undervalued by 397.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$457.53 Million
Enterprise Value$5.83 Million
Dividend Yield$0 (0%)
Earnings per Share$-2.27
Beta0.07
Outstanding Shares53,815,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-3.74
PEG1.01
Price to Sales3.55
Price to Book Ratio0.79
Enterprise Value to Revenue0.04
Enterprise Value to EBIT-0.04
Enterprise Value to Net Income-1
Total Debt to Enterprise3.38
Debt to Equity0.04

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Prothena Corporation plc

7 employees
CEO: Gene Kinney

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and r...